Home » Topics » BioWorld Science

BioWorld Science
RSS

BioCryst completes phase I study of intravenous galidesivir in healthy subjects

May 10, 2019

Mustang announces new phase I trial of CAR T-cell therapy for multiple myeloma

May 10, 2019

Aptose begins phase Ia/Ib study of CG-806 in CLL, SLL and NHL

May 10, 2019

New phase I trial explores Precigen's PRGN-3005 UltraCAR-T cells for advanced ovarian cancer

May 10, 2019

Tempest Therapeutics divulges IDO1 inhibitors

May 10, 2019

eFFECTOR Therapeutics describes MNK1 and MNK2 inhibitors

May 10, 2019

Epizyme discloses EHMT1 and/or EHMT2 inhibitors

May 10, 2019

Incyte patents PI3Kgamma inhibitors

May 10, 2019

Bristol-Myers Squibb presents new hSTING agonists

May 10, 2019

CAR T-cell therapy targeting AMHR2, a potential treatment for ovarian cancer

May 10, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...